nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2C8—Mometasone—systemic scleroderma	0.175	0.294	CbGbCtD
Loperamide—ABCB1—Lisinopril—systemic scleroderma	0.0798	0.134	CbGbCtD
Loperamide—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0695	0.117	CbGbCtD
Loperamide—ABCB1—Captopril—systemic scleroderma	0.0597	0.101	CbGbCtD
Loperamide—CYP2D6—Captopril—systemic scleroderma	0.0563	0.0948	CbGbCtD
Loperamide—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.047	0.0792	CbGbCtD
Loperamide—ABCB1—Prednisone—systemic scleroderma	0.0376	0.0633	CbGbCtD
Loperamide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0282	0.0474	CbGbCtD
Loperamide—CYP3A4—Prednisone—systemic scleroderma	0.0225	0.0379	CbGbCtD
Loperamide—ABCB1—Methotrexate—systemic scleroderma	0.0189	0.0318	CbGbCtD
Loperamide—POMC—blood vessel—systemic scleroderma	0.013	0.148	CbGeAlD
Loperamide—POMC—connective tissue—systemic scleroderma	0.00664	0.0758	CbGeAlD
Loperamide—POMC—skin of body—systemic scleroderma	0.006	0.0685	CbGeAlD
Loperamide—POMC—digestive system—systemic scleroderma	0.0048	0.0548	CbGeAlD
Loperamide—CALM2—artery—systemic scleroderma	0.00454	0.0519	CbGeAlD
Loperamide—CALM1—artery—systemic scleroderma	0.00452	0.0516	CbGeAlD
Loperamide—POMC—lung—systemic scleroderma	0.00401	0.0457	CbGeAlD
Loperamide—CALM2—endothelium—systemic scleroderma	0.00384	0.0438	CbGeAlD
Loperamide—CALM1—endothelium—systemic scleroderma	0.00382	0.0436	CbGeAlD
Loperamide—CALM2—blood vessel—systemic scleroderma	0.00354	0.0404	CbGeAlD
Loperamide—CALM1—blood vessel—systemic scleroderma	0.00352	0.0402	CbGeAlD
Loperamide—CALM3—smooth muscle tissue—systemic scleroderma	0.00211	0.0241	CbGeAlD
Loperamide—CALM2—connective tissue—systemic scleroderma	0.00181	0.0207	CbGeAlD
Loperamide—CALM1—connective tissue—systemic scleroderma	0.00181	0.0206	CbGeAlD
Loperamide—CALM2—smooth muscle tissue—systemic scleroderma	0.00166	0.0189	CbGeAlD
Loperamide—CALM1—smooth muscle tissue—systemic scleroderma	0.00165	0.0189	CbGeAlD
Loperamide—CALM2—skin of body—systemic scleroderma	0.00164	0.0187	CbGeAlD
Loperamide—CALM1—skin of body—systemic scleroderma	0.00163	0.0186	CbGeAlD
Loperamide—CALM3—tendon—systemic scleroderma	0.00159	0.0181	CbGeAlD
Loperamide—Abdominal pain upper—Mycophenolic acid—systemic scleroderma	0.00152	0.00624	CcSEcCtD
Loperamide—Immune system disorder—Mometasone—systemic scleroderma	0.0015	0.00618	CcSEcCtD
Loperamide—Abdominal distension—Mycophenolic acid—systemic scleroderma	0.00145	0.00594	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.00142	0.00584	CcSEcCtD
Loperamide—Discomfort—Pentoxifylline—systemic scleroderma	0.00141	0.00581	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Azathioprine—systemic scleroderma	0.00141	0.00579	CcSEcCtD
Loperamide—ABCB1—blood vessel—systemic scleroderma	0.00141	0.0161	CbGeAlD
Loperamide—Dry mouth—Pentoxifylline—systemic scleroderma	0.0014	0.00575	CcSEcCtD
Loperamide—CALM3—lung—systemic scleroderma	0.00139	0.0159	CbGeAlD
Loperamide—Erythema multiforme—Captopril—systemic scleroderma	0.00138	0.00568	CcSEcCtD
Loperamide—Dermatitis bullous—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00564	CcSEcCtD
Loperamide—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.00137	0.00564	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Lisinopril—systemic scleroderma	0.00135	0.00554	CcSEcCtD
Loperamide—Skin disorder—Pentoxifylline—systemic scleroderma	0.00133	0.00547	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Leflunomide—systemic scleroderma	0.00133	0.00547	CcSEcCtD
Loperamide—Angioedema—Mometasone—systemic scleroderma	0.00132	0.00544	CcSEcCtD
Loperamide—CALM2—digestive system—systemic scleroderma	0.00131	0.015	CbGeAlD
Loperamide—CALM1—digestive system—systemic scleroderma	0.0013	0.0149	CbGeAlD
Loperamide—CALM2—tendon—systemic scleroderma	0.00125	0.0142	CbGeAlD
Loperamide—Urinary retention—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00513	CcSEcCtD
Loperamide—CALM1—tendon—systemic scleroderma	0.00124	0.0142	CbGeAlD
Loperamide—Somnolence—Pentoxifylline—systemic scleroderma	0.00122	0.00501	CcSEcCtD
Loperamide—CYP2B6—skin of body—systemic scleroderma	0.00122	0.0139	CbGeAlD
Loperamide—Dry mouth—Mometasone—systemic scleroderma	0.00121	0.00496	CcSEcCtD
Loperamide—Dyspepsia—Pentoxifylline—systemic scleroderma	0.00121	0.00496	CcSEcCtD
Loperamide—Erythema multiforme—Azathioprine—systemic scleroderma	0.00121	0.00496	CcSEcCtD
Loperamide—Urinary tract disorder—Leflunomide—systemic scleroderma	0.00119	0.00489	CcSEcCtD
Loperamide—Anaphylactic shock—Mometasone—systemic scleroderma	0.00118	0.00486	CcSEcCtD
Loperamide—Urethral disorder—Leflunomide—systemic scleroderma	0.00118	0.00486	CcSEcCtD
Loperamide—Constipation—Pentoxifylline—systemic scleroderma	0.00117	0.00482	CcSEcCtD
Loperamide—Angioedema—Captopril—systemic scleroderma	0.00116	0.00478	CcSEcCtD
Loperamide—Immune system disorder—Azathioprine—systemic scleroderma	0.00115	0.00474	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Lisinopril—systemic scleroderma	0.00114	0.0047	CcSEcCtD
Loperamide—Abdominal distension—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00469	CcSEcCtD
Loperamide—Erythema multiforme—Leflunomide—systemic scleroderma	0.00114	0.00468	CcSEcCtD
Loperamide—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.00114	0.00467	CcSEcCtD
Loperamide—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.00113	0.00463	CcSEcCtD
Loperamide—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.00112	0.00461	CcSEcCtD
Loperamide—Loss of consciousness—Captopril—systemic scleroderma	0.00112	0.0046	CcSEcCtD
Loperamide—CALM2—lung—systemic scleroderma	0.00109	0.0125	CbGeAlD
Loperamide—CALM1—lung—systemic scleroderma	0.00109	0.0124	CbGeAlD
Loperamide—Urticaria—Pentoxifylline—systemic scleroderma	0.00109	0.00448	CcSEcCtD
Loperamide—Immune system disorder—Leflunomide—systemic scleroderma	0.00109	0.00448	CcSEcCtD
Loperamide—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00108	0.00445	CcSEcCtD
Loperamide—Discomfort—Captopril—systemic scleroderma	0.00107	0.0044	CcSEcCtD
Loperamide—Dry mouth—Captopril—systemic scleroderma	0.00106	0.00436	CcSEcCtD
Loperamide—Dyspepsia—Mometasone—systemic scleroderma	0.00104	0.00428	CcSEcCtD
Loperamide—Anaphylactic shock—Captopril—systemic scleroderma	0.00104	0.00427	CcSEcCtD
Loperamide—Flatulence—Leflunomide—systemic scleroderma	0.00103	0.00425	CcSEcCtD
Loperamide—Urinary tract disorder—Lisinopril—systemic scleroderma	0.00102	0.0042	CcSEcCtD
Loperamide—Fatigue—Mometasone—systemic scleroderma	0.00102	0.00419	CcSEcCtD
Loperamide—Urethral disorder—Lisinopril—systemic scleroderma	0.00101	0.00417	CcSEcCtD
Loperamide—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00101	0.00415	CcSEcCtD
Loperamide—Depressed level of consciousness—Methotrexate—systemic scleroderma	0.000988	0.00406	CcSEcCtD
Loperamide—Flatulence—Mycophenolic acid—systemic scleroderma	0.000986	0.00405	CcSEcCtD
Loperamide—Asthenia—Pentoxifylline—systemic scleroderma	0.000983	0.00404	CcSEcCtD
Loperamide—Erythema multiforme—Lisinopril—systemic scleroderma	0.000979	0.00403	CcSEcCtD
Loperamide—CYP2B6—digestive system—systemic scleroderma	0.000974	0.0111	CbGeAlD
Loperamide—Pruritus—Pentoxifylline—systemic scleroderma	0.00097	0.00399	CcSEcCtD
Loperamide—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000967	0.00398	CcSEcCtD
Loperamide—Angioedema—Leflunomide—systemic scleroderma	0.000958	0.00394	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000939	0.00386	CcSEcCtD
Loperamide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000938	0.00386	CcSEcCtD
Loperamide—Abdominal pain—Mometasone—systemic scleroderma	0.000935	0.00384	CcSEcCtD
Loperamide—Discomfort—Azathioprine—systemic scleroderma	0.000934	0.00384	CcSEcCtD
Loperamide—Somnolence—Captopril—systemic scleroderma	0.000923	0.0038	CcSEcCtD
Loperamide—Dyspepsia—Captopril—systemic scleroderma	0.000914	0.00376	CcSEcCtD
Loperamide—Dizziness—Pentoxifylline—systemic scleroderma	0.000906	0.00373	CcSEcCtD
Loperamide—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000896	0.00368	CcSEcCtD
Loperamide—Fatigue—Captopril—systemic scleroderma	0.000895	0.00368	CcSEcCtD
Loperamide—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000889	0.00366	CcSEcCtD
Loperamide—Constipation—Captopril—systemic scleroderma	0.000888	0.00365	CcSEcCtD
Loperamide—Flatulence—Lisinopril—systemic scleroderma	0.000888	0.00365	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000887	0.00365	CcSEcCtD
Loperamide—Discomfort—Leflunomide—systemic scleroderma	0.000882	0.00363	CcSEcCtD
Loperamide—Skin disorder—Azathioprine—systemic scleroderma	0.00088	0.00362	CcSEcCtD
Loperamide—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000879	0.00362	CcSEcCtD
Loperamide—Dry mouth—Leflunomide—systemic scleroderma	0.000873	0.00359	CcSEcCtD
Loperamide—Vomiting—Pentoxifylline—systemic scleroderma	0.000871	0.00358	CcSEcCtD
Loperamide—Rash—Pentoxifylline—systemic scleroderma	0.000864	0.00355	CcSEcCtD
Loperamide—Dermatitis—Pentoxifylline—systemic scleroderma	0.000863	0.00355	CcSEcCtD
Loperamide—Headache—Pentoxifylline—systemic scleroderma	0.000859	0.00353	CcSEcCtD
Loperamide—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000856	0.00352	CcSEcCtD
Loperamide—Gastrointestinal pain—Captopril—systemic scleroderma	0.000849	0.00349	CcSEcCtD
Loperamide—Asthenia—Mometasone—systemic scleroderma	0.000848	0.00349	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000846	0.00348	CcSEcCtD
Loperamide—Discomfort—Mycophenolic acid—systemic scleroderma	0.000842	0.00346	CcSEcCtD
Loperamide—Nervous system disorder—Leflunomide—systemic scleroderma	0.000839	0.00345	CcSEcCtD
Loperamide—Pruritus—Mometasone—systemic scleroderma	0.000837	0.00344	CcSEcCtD
Loperamide—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000833	0.00343	CcSEcCtD
Loperamide—Skin disorder—Leflunomide—systemic scleroderma	0.000831	0.00342	CcSEcCtD
Loperamide—Angioedema—Lisinopril—systemic scleroderma	0.000823	0.00339	CcSEcCtD
Loperamide—Abdominal pain—Captopril—systemic scleroderma	0.000821	0.00338	CcSEcCtD
Loperamide—Nausea—Pentoxifylline—systemic scleroderma	0.000814	0.00335	CcSEcCtD
Loperamide—CYP2B6—lung—systemic scleroderma	0.000814	0.00929	CbGeAlD
Loperamide—Diarrhoea—Mometasone—systemic scleroderma	0.000809	0.00333	CcSEcCtD
Loperamide—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000801	0.00329	CcSEcCtD
Loperamide—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000793	0.00326	CcSEcCtD
Loperamide—Loss of consciousness—Lisinopril—systemic scleroderma	0.000792	0.00326	CcSEcCtD
Loperamide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000783	0.00322	CcSEcCtD
Loperamide—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000778	0.0032	CcSEcCtD
Loperamide—Abdominal distension—Prednisone—systemic scleroderma	0.000773	0.00318	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000767	0.00316	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000762	0.00313	CcSEcCtD
Loperamide—Discomfort—Lisinopril—systemic scleroderma	0.000758	0.00312	CcSEcCtD
Loperamide—Dyspepsia—Leflunomide—systemic scleroderma	0.000753	0.0031	CcSEcCtD
Loperamide—Vomiting—Mometasone—systemic scleroderma	0.000752	0.00309	CcSEcCtD
Loperamide—Dry mouth—Lisinopril—systemic scleroderma	0.00075	0.00309	CcSEcCtD
Loperamide—Rash—Mometasone—systemic scleroderma	0.000746	0.00307	CcSEcCtD
Loperamide—Asthenia—Captopril—systemic scleroderma	0.000745	0.00306	CcSEcCtD
Loperamide—Dermatitis—Mometasone—systemic scleroderma	0.000745	0.00306	CcSEcCtD
Loperamide—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000741	0.00305	CcSEcCtD
Loperamide—Headache—Mometasone—systemic scleroderma	0.000741	0.00305	CcSEcCtD
Loperamide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000739	0.00304	CcSEcCtD
Loperamide—Fatigue—Leflunomide—systemic scleroderma	0.000738	0.00303	CcSEcCtD
Loperamide—CYP3A4—digestive system—systemic scleroderma	0.000736	0.0084	CbGeAlD
Loperamide—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000735	0.00302	CcSEcCtD
Loperamide—Pruritus—Captopril—systemic scleroderma	0.000735	0.00302	CcSEcCtD
Loperamide—Constipation—Leflunomide—systemic scleroderma	0.000732	0.00301	CcSEcCtD
Loperamide—Somnolence—Mycophenolic acid—systemic scleroderma	0.000726	0.00299	CcSEcCtD
Loperamide—CYP2D6—digestive system—systemic scleroderma	0.000724	0.00826	CbGeAlD
Loperamide—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000721	0.00297	CcSEcCtD
Loperamide—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000719	0.00296	CcSEcCtD
Loperamide—Abdominal pain—Azathioprine—systemic scleroderma	0.000717	0.00295	CcSEcCtD
Loperamide—Skin disorder—Lisinopril—systemic scleroderma	0.000714	0.00294	CcSEcCtD
Loperamide—Diarrhoea—Captopril—systemic scleroderma	0.000711	0.00292	CcSEcCtD
Loperamide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000705	0.0029	CcSEcCtD
Loperamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000704	0.0029	CcSEcCtD
Loperamide—Nausea—Mometasone—systemic scleroderma	0.000702	0.00289	CcSEcCtD
Loperamide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.0007	0.00288	CcSEcCtD
Loperamide—Constipation—Mycophenolic acid—systemic scleroderma	0.000698	0.00287	CcSEcCtD
Loperamide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000694	0.00285	CcSEcCtD
Loperamide—Dizziness—Captopril—systemic scleroderma	0.000687	0.00282	CcSEcCtD
Loperamide—Urticaria—Leflunomide—systemic scleroderma	0.00068	0.0028	CcSEcCtD
Loperamide—Abdominal pain—Leflunomide—systemic scleroderma	0.000677	0.00278	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000669	0.00275	CcSEcCtD
Loperamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000668	0.00275	CcSEcCtD
Loperamide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000668	0.00275	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000668	0.00275	CcSEcCtD
Loperamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000664	0.00273	CcSEcCtD
Loperamide—Vomiting—Captopril—systemic scleroderma	0.00066	0.00272	CcSEcCtD
Loperamide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000657	0.0027	CcSEcCtD
Loperamide—Rash—Captopril—systemic scleroderma	0.000655	0.00269	CcSEcCtD
Loperamide—Dermatitis—Captopril—systemic scleroderma	0.000654	0.00269	CcSEcCtD
Loperamide—Somnolence—Lisinopril—systemic scleroderma	0.000654	0.00269	CcSEcCtD
Loperamide—Headache—Captopril—systemic scleroderma	0.000651	0.00268	CcSEcCtD
Loperamide—Dyspepsia—Lisinopril—systemic scleroderma	0.000647	0.00266	CcSEcCtD
Loperamide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000646	0.00265	CcSEcCtD
Loperamide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000644	0.00265	CcSEcCtD
Loperamide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000635	0.00261	CcSEcCtD
Loperamide—Fatigue—Lisinopril—systemic scleroderma	0.000634	0.00261	CcSEcCtD
Loperamide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000632	0.0026	CcSEcCtD
Loperamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000631	0.00259	CcSEcCtD
Loperamide—Constipation—Lisinopril—systemic scleroderma	0.000629	0.00259	CcSEcCtD
Loperamide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000626	0.00257	CcSEcCtD
Loperamide—Diarrhoea—Azathioprine—systemic scleroderma	0.00062	0.00255	CcSEcCtD
Loperamide—Nausea—Captopril—systemic scleroderma	0.000617	0.00254	CcSEcCtD
Loperamide—Asthenia—Leflunomide—systemic scleroderma	0.000614	0.00253	CcSEcCtD
Loperamide—Pruritus—Leflunomide—systemic scleroderma	0.000606	0.00249	CcSEcCtD
Loperamide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000601	0.00247	CcSEcCtD
Loperamide—Dizziness—Azathioprine—systemic scleroderma	0.000599	0.00246	CcSEcCtD
Loperamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000586	0.00241	CcSEcCtD
Loperamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000586	0.00241	CcSEcCtD
Loperamide—Urticaria—Lisinopril—systemic scleroderma	0.000584	0.0024	CcSEcCtD
Loperamide—Abdominal pain—Lisinopril—systemic scleroderma	0.000581	0.00239	CcSEcCtD
Loperamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000578	0.00238	CcSEcCtD
Loperamide—Vomiting—Azathioprine—systemic scleroderma	0.000576	0.00237	CcSEcCtD
Loperamide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000573	0.00236	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—systemic scleroderma	0.000572	0.00235	CcSEcCtD
Loperamide—Rash—Azathioprine—systemic scleroderma	0.000571	0.00235	CcSEcCtD
Loperamide—Dermatitis—Azathioprine—systemic scleroderma	0.000571	0.00235	CcSEcCtD
Loperamide—Headache—Azathioprine—systemic scleroderma	0.000568	0.00234	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000567	0.00233	CcSEcCtD
Loperamide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000567	0.00233	CcSEcCtD
Loperamide—Dizziness—Leflunomide—systemic scleroderma	0.000566	0.00233	CcSEcCtD
Loperamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000559	0.0023	CcSEcCtD
Loperamide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000556	0.00229	CcSEcCtD
Loperamide—Immune system disorder—Prednisone—systemic scleroderma	0.000555	0.00228	CcSEcCtD
Loperamide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000551	0.00227	CcSEcCtD
Loperamide—Vomiting—Leflunomide—systemic scleroderma	0.000544	0.00224	CcSEcCtD
Loperamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000542	0.00223	CcSEcCtD
Loperamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.00054	0.00222	CcSEcCtD
Loperamide—Rash—Leflunomide—systemic scleroderma	0.00054	0.00222	CcSEcCtD
Loperamide—Dermatitis—Leflunomide—systemic scleroderma	0.000539	0.00222	CcSEcCtD
Loperamide—Nausea—Azathioprine—systemic scleroderma	0.000538	0.00221	CcSEcCtD
Loperamide—Headache—Leflunomide—systemic scleroderma	0.000536	0.00221	CcSEcCtD
Loperamide—Asthenia—Lisinopril—systemic scleroderma	0.000528	0.00217	CcSEcCtD
Loperamide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000527	0.00217	CcSEcCtD
Loperamide—ABCB1—digestive system—systemic scleroderma	0.000521	0.00594	CbGeAlD
Loperamide—Pruritus—Lisinopril—systemic scleroderma	0.00052	0.00214	CcSEcCtD
Loperamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000519	0.00214	CcSEcCtD
Loperamide—Rash—Mycophenolic acid—systemic scleroderma	0.000515	0.00212	CcSEcCtD
Loperamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000514	0.00212	CcSEcCtD
Loperamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000512	0.00211	CcSEcCtD
Loperamide—Headache—Mycophenolic acid—systemic scleroderma	0.000512	0.0021	CcSEcCtD
Loperamide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000509	0.00209	CcSEcCtD
Loperamide—Nausea—Leflunomide—systemic scleroderma	0.000508	0.00209	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000507	0.00209	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—systemic scleroderma	0.000504	0.00207	CcSEcCtD
Loperamide—Diarrhoea—Lisinopril—systemic scleroderma	0.000503	0.00207	CcSEcCtD
Loperamide—Angioedema—Prednisone—systemic scleroderma	0.000489	0.00201	CcSEcCtD
Loperamide—Dizziness—Lisinopril—systemic scleroderma	0.000486	0.002	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000486	0.002	CcSEcCtD
Loperamide—Nausea—Mycophenolic acid—systemic scleroderma	0.000485	0.00199	CcSEcCtD
Loperamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000475	0.00195	CcSEcCtD
Loperamide—Loss of consciousness—Prednisone—systemic scleroderma	0.00047	0.00193	CcSEcCtD
Loperamide—Vomiting—Lisinopril—systemic scleroderma	0.000468	0.00192	CcSEcCtD
Loperamide—Immune system disorder—Methotrexate—systemic scleroderma	0.000464	0.00191	CcSEcCtD
Loperamide—Rash—Lisinopril—systemic scleroderma	0.000464	0.00191	CcSEcCtD
Loperamide—Dermatitis—Lisinopril—systemic scleroderma	0.000463	0.00191	CcSEcCtD
Loperamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000462	0.0019	CcSEcCtD
Loperamide—Headache—Lisinopril—systemic scleroderma	0.000461	0.00189	CcSEcCtD
Loperamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000456	0.00187	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000453	0.00186	CcSEcCtD
Loperamide—Discomfort—Prednisone—systemic scleroderma	0.00045	0.00185	CcSEcCtD
Loperamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000441	0.00181	CcSEcCtD
Loperamide—Nausea—Lisinopril—systemic scleroderma	0.000437	0.0018	CcSEcCtD
Loperamide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000437	0.0018	CcSEcCtD
Loperamide—ABCB1—lung—systemic scleroderma	0.000435	0.00496	CbGeAlD
Loperamide—Nervous system disorder—Prednisone—systemic scleroderma	0.000428	0.00176	CcSEcCtD
Loperamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000426	0.00175	CcSEcCtD
Loperamide—Skin disorder—Prednisone—systemic scleroderma	0.000424	0.00174	CcSEcCtD
Loperamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00041	0.00168	CcSEcCtD
Loperamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000406	0.00167	CcSEcCtD
Loperamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000406	0.00167	CcSEcCtD
Loperamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000404	0.00166	CcSEcCtD
Loperamide—Dyspepsia—Prednisone—systemic scleroderma	0.000385	0.00158	CcSEcCtD
Loperamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000383	0.00157	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000378	0.00156	CcSEcCtD
Loperamide—Fatigue—Prednisone—systemic scleroderma	0.000377	0.00155	CcSEcCtD
Loperamide—Discomfort—Methotrexate—systemic scleroderma	0.000376	0.00155	CcSEcCtD
Loperamide—Constipation—Prednisone—systemic scleroderma	0.000374	0.00154	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000365	0.0015	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000358	0.00147	CcSEcCtD
Loperamide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000357	0.00147	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—systemic scleroderma	0.000355	0.00146	CcSEcCtD
Loperamide—Urticaria—Prednisone—systemic scleroderma	0.000347	0.00143	CcSEcCtD
Loperamide—Abdominal pain—Prednisone—systemic scleroderma	0.000345	0.00142	CcSEcCtD
Loperamide—Somnolence—Methotrexate—systemic scleroderma	0.000325	0.00133	CcSEcCtD
Loperamide—Hypersensitivity—Prednisone—systemic scleroderma	0.000322	0.00132	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—systemic scleroderma	0.000321	0.00132	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000315	0.0013	CcSEcCtD
Loperamide—Fatigue—Methotrexate—systemic scleroderma	0.000315	0.00129	CcSEcCtD
Loperamide—Asthenia—Prednisone—systemic scleroderma	0.000313	0.00129	CcSEcCtD
Loperamide—Pruritus—Prednisone—systemic scleroderma	0.000309	0.00127	CcSEcCtD
Loperamide—Diarrhoea—Prednisone—systemic scleroderma	0.000299	0.00123	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000299	0.00123	CcSEcCtD
Loperamide—Urticaria—Methotrexate—systemic scleroderma	0.00029	0.00119	CcSEcCtD
Loperamide—Dizziness—Prednisone—systemic scleroderma	0.000289	0.00119	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—systemic scleroderma	0.000289	0.00119	CcSEcCtD
Loperamide—Vomiting—Prednisone—systemic scleroderma	0.000278	0.00114	CcSEcCtD
Loperamide—Rash—Prednisone—systemic scleroderma	0.000275	0.00113	CcSEcCtD
Loperamide—Dermatitis—Prednisone—systemic scleroderma	0.000275	0.00113	CcSEcCtD
Loperamide—Headache—Prednisone—systemic scleroderma	0.000274	0.00113	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000269	0.00111	CcSEcCtD
Loperamide—Asthenia—Methotrexate—systemic scleroderma	0.000262	0.00108	CcSEcCtD
Loperamide—Nausea—Prednisone—systemic scleroderma	0.000259	0.00107	CcSEcCtD
Loperamide—Pruritus—Methotrexate—systemic scleroderma	0.000258	0.00106	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—systemic scleroderma	0.00025	0.00103	CcSEcCtD
Loperamide—Dizziness—Methotrexate—systemic scleroderma	0.000241	0.000993	CcSEcCtD
Loperamide—Vomiting—Methotrexate—systemic scleroderma	0.000232	0.000955	CcSEcCtD
Loperamide—Rash—Methotrexate—systemic scleroderma	0.00023	0.000947	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—systemic scleroderma	0.00023	0.000946	CcSEcCtD
Loperamide—Headache—Methotrexate—systemic scleroderma	0.000229	0.00094	CcSEcCtD
Loperamide—Nausea—Methotrexate—systemic scleroderma	0.000217	0.000892	CcSEcCtD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000127	0.00169	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—CCL2—systemic scleroderma	0.000125	0.00166	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—RHOB—systemic scleroderma	0.000125	0.00166	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—EDN1—systemic scleroderma	0.000124	0.00165	CbGpPWpGaD
Loperamide—CALM3—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000123	0.00163	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—SELP—systemic scleroderma	0.000122	0.00162	CbGpPWpGaD
Loperamide—CALM2—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000119	0.00158	CbGpPWpGaD
Loperamide—CALM1—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000119	0.00158	CbGpPWpGaD
Loperamide—CALM2—Endochondral Ossification—TGFB1—systemic scleroderma	0.000118	0.00157	CbGpPWpGaD
Loperamide—CALM1—Endochondral Ossification—TGFB1—systemic scleroderma	0.000118	0.00157	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—SELP—systemic scleroderma	0.000118	0.00157	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—SELP—systemic scleroderma	0.000118	0.00157	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000116	0.00154	CbGpPWpGaD
Loperamide—CALM3—Signaling by VEGF—NOS3—systemic scleroderma	0.000116	0.00154	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—RHOB—systemic scleroderma	0.000114	0.00151	CbGpPWpGaD
Loperamide—CALM1—Signaling by VEGF—NOS3—systemic scleroderma	0.000112	0.00149	CbGpPWpGaD
Loperamide—CALM2—Signaling by VEGF—NOS3—systemic scleroderma	0.000112	0.00149	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000111	0.00148	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—RHOB—systemic scleroderma	0.00011	0.00146	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—RHOB—systemic scleroderma	0.00011	0.00146	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—SMAD7—systemic scleroderma	0.000109	0.00144	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—EDN1—systemic scleroderma	0.000108	0.00144	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—RHOB—systemic scleroderma	0.000105	0.0014	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—EDN1—systemic scleroderma	0.000105	0.00139	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—CSK—systemic scleroderma	0.000104	0.00138	CbGpPWpGaD
Loperamide—CALM3—Platelet degranulation—TGFB1—systemic scleroderma	0.000102	0.00136	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	0.000101	0.00134	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—CSK—systemic scleroderma	0.0001	0.00133	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—CSK—systemic scleroderma	0.0001	0.00133	CbGpPWpGaD
Loperamide—CALM2—Platelet degranulation—TGFB1—systemic scleroderma	9.89e-05	0.00132	CbGpPWpGaD
Loperamide—CALM1—Platelet degranulation—TGFB1—systemic scleroderma	9.89e-05	0.00132	CbGpPWpGaD
Loperamide—CALM3—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	9.74e-05	0.0013	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—ITGAM—systemic scleroderma	9.74e-05	0.00129	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—CCL2—systemic scleroderma	9.67e-05	0.00129	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—SMAD7—systemic scleroderma	9.52e-05	0.00127	CbGpPWpGaD
Loperamide—CALM1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	9.52e-05	0.00127	CbGpPWpGaD
Loperamide—CALM2—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	9.52e-05	0.00127	CbGpPWpGaD
Loperamide—CALM1—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	9.43e-05	0.00125	CbGpPWpGaD
Loperamide—CALM2—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	9.43e-05	0.00125	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—ITGAM—systemic scleroderma	9.42e-05	0.00125	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—ITGAM—systemic scleroderma	9.42e-05	0.00125	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	9.41e-05	0.00125	CbGpPWpGaD
Loperamide—CALM3—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	9.11e-05	0.00121	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CSK—systemic scleroderma	8.95e-05	0.00119	CbGpPWpGaD
Loperamide—CALM2—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	8.82e-05	0.00117	CbGpPWpGaD
Loperamide—CALM1—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	8.82e-05	0.00117	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—CD247—systemic scleroderma	8.76e-05	0.00117	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—ITGAM—systemic scleroderma	8.76e-05	0.00117	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CSK—systemic scleroderma	8.66e-05	0.00115	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CSK—systemic scleroderma	8.66e-05	0.00115	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.49e-05	0.00113	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—CCL2—systemic scleroderma	8.48e-05	0.00113	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—CD247—systemic scleroderma	8.48e-05	0.00113	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—CD247—systemic scleroderma	8.48e-05	0.00113	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—ITGAM—systemic scleroderma	8.48e-05	0.00113	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—ITGAM—systemic scleroderma	8.48e-05	0.00113	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD247—systemic scleroderma	8.42e-05	0.00112	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—RHOB—systemic scleroderma	8.4e-05	0.00112	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—TNFAIP3—systemic scleroderma	8.21e-05	0.00109	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD247—systemic scleroderma	8.14e-05	0.00108	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD247—systemic scleroderma	8.14e-05	0.00108	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SMAD7—systemic scleroderma	8.05e-05	0.00107	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—EDN1—systemic scleroderma	8e-05	0.00106	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—TNFAIP3—systemic scleroderma	7.94e-05	0.00106	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—TNFAIP3—systemic scleroderma	7.94e-05	0.00106	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HSPG2—systemic scleroderma	7.92e-05	0.00105	CbGpPWpGaD
Loperamide—POMC—Metabolism—NOS3—systemic scleroderma	7.88e-05	0.00105	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	7.83e-05	0.00104	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—BLK—systemic scleroderma	7.79e-05	0.00104	CbGpPWpGaD
Loperamide—CALM3—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	7.75e-05	0.00103	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CSK—systemic scleroderma	7.65e-05	0.00102	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—BLK—systemic scleroderma	7.53e-05	0.001	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—BLK—systemic scleroderma	7.53e-05	0.001	CbGpPWpGaD
Loperamide—CALM1—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	7.5e-05	0.000998	CbGpPWpGaD
Loperamide—CALM2—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	7.5e-05	0.000998	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—CCL2—systemic scleroderma	7.39e-05	0.000983	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—RHOB—systemic scleroderma	7.37e-05	0.00098	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—EDN1—systemic scleroderma	7.26e-05	0.000966	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—CCL2—systemic scleroderma	7.17e-05	0.000954	CbGpPWpGaD
Loperamide—CALM3—Disease—SMAD7—systemic scleroderma	7.11e-05	0.000946	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—EDN1—systemic scleroderma	7.01e-05	0.000933	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HSPG2—systemic scleroderma	6.95e-05	0.000924	CbGpPWpGaD
Loperamide—CALM2—Disease—SMAD7—systemic scleroderma	6.88e-05	0.000916	CbGpPWpGaD
Loperamide—CALM1—Disease—SMAD7—systemic scleroderma	6.88e-05	0.000916	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—NOS3—systemic scleroderma	6.81e-05	0.000906	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CSK—systemic scleroderma	6.71e-05	0.000893	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—NOS3—systemic scleroderma	6.59e-05	0.000876	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—RHOB—systemic scleroderma	6.52e-05	0.000868	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFBI—systemic scleroderma	6.51e-05	0.000866	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.43e-05	0.000856	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CTLA4—systemic scleroderma	6.38e-05	0.000848	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—EDN1—systemic scleroderma	6.37e-05	0.000847	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—RHOB—systemic scleroderma	6.31e-05	0.00084	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—RHOB—systemic scleroderma	6.31e-05	0.00084	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFBI—systemic scleroderma	6.29e-05	0.000837	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFBI—systemic scleroderma	6.29e-05	0.000837	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—RHOB—systemic scleroderma	6.23e-05	0.000828	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CTLA4—systemic scleroderma	6.17e-05	0.000821	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CTLA4—systemic scleroderma	6.17e-05	0.000821	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—EDN1—systemic scleroderma	5.93e-05	0.000788	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HSPG2—systemic scleroderma	5.87e-05	0.000781	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CSK—systemic scleroderma	5.67e-05	0.000754	CbGpPWpGaD
Loperamide—CALM3—Immune System—CSK—systemic scleroderma	5.43e-05	0.000722	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—EDN1—systemic scleroderma	5.38e-05	0.000716	CbGpPWpGaD
Loperamide—CALM3—Immune System—IRF5—systemic scleroderma	5.34e-05	0.000711	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—MMP9—systemic scleroderma	5.28e-05	0.000703	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-DQB1—systemic scleroderma	5.25e-05	0.000699	CbGpPWpGaD
Loperamide—CALM1—Immune System—CSK—systemic scleroderma	5.25e-05	0.000699	CbGpPWpGaD
Loperamide—CALM2—Immune System—CSK—systemic scleroderma	5.25e-05	0.000699	CbGpPWpGaD
Loperamide—CALM3—Disease—HSPG2—systemic scleroderma	5.19e-05	0.00069	CbGpPWpGaD
Loperamide—CALM2—Immune System—IRF5—systemic scleroderma	5.17e-05	0.000687	CbGpPWpGaD
Loperamide—CALM1—Immune System—IRF5—systemic scleroderma	5.17e-05	0.000687	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD247—systemic scleroderma	5.1e-05	0.000679	CbGpPWpGaD
Loperamide—CALM3—Immune System—ITGAM—systemic scleroderma	5.1e-05	0.000679	CbGpPWpGaD
Loperamide—CALM3—Immune System—IRF8—systemic scleroderma	5.1e-05	0.000679	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	5.08e-05	0.000676	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	5.08e-05	0.000676	CbGpPWpGaD
Loperamide—CALM2—Disease—HSPG2—systemic scleroderma	5.02e-05	0.000668	CbGpPWpGaD
Loperamide—CALM1—Disease—HSPG2—systemic scleroderma	5.02e-05	0.000668	CbGpPWpGaD
Loperamide—CALM3—Disease—CSK—systemic scleroderma	5.01e-05	0.000667	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SMAD7—systemic scleroderma	4.98e-05	0.000663	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—CCL2—systemic scleroderma	4.96e-05	0.00066	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD40LG—systemic scleroderma	4.96e-05	0.00066	CbGpPWpGaD
Loperamide—CALM1—Immune System—IRF8—systemic scleroderma	4.94e-05	0.000657	CbGpPWpGaD
Loperamide—CALM2—Immune System—IRF8—systemic scleroderma	4.94e-05	0.000657	CbGpPWpGaD
Loperamide—CALM1—Immune System—ITGAM—systemic scleroderma	4.94e-05	0.000657	CbGpPWpGaD
Loperamide—CALM2—Immune System—ITGAM—systemic scleroderma	4.94e-05	0.000657	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD247—systemic scleroderma	4.94e-05	0.000657	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD247—systemic scleroderma	4.94e-05	0.000657	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—MMP1—systemic scleroderma	4.88e-05	0.000649	CbGpPWpGaD
Loperamide—CALM2—Disease—CSK—systemic scleroderma	4.85e-05	0.000645	CbGpPWpGaD
Loperamide—CALM1—Disease—CSK—systemic scleroderma	4.85e-05	0.000645	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SMAD7—systemic scleroderma	4.82e-05	0.000641	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SMAD7—systemic scleroderma	4.82e-05	0.000641	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD40LG—systemic scleroderma	4.8e-05	0.000638	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD40LG—systemic scleroderma	4.8e-05	0.000638	CbGpPWpGaD
Loperamide—CALM3—Immune System—TNFAIP3—systemic scleroderma	4.78e-05	0.000636	CbGpPWpGaD
Loperamide—CALM3—Immune System—BLK—systemic scleroderma	4.72e-05	0.000628	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—MMP1—systemic scleroderma	4.72e-05	0.000628	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—MMP1—systemic scleroderma	4.72e-05	0.000628	CbGpPWpGaD
Loperamide—CALM3—Disease—CD247—systemic scleroderma	4.71e-05	0.000627	CbGpPWpGaD
Loperamide—CALM2—Immune System—TNFAIP3—systemic scleroderma	4.62e-05	0.000615	CbGpPWpGaD
Loperamide—CALM1—Immune System—TNFAIP3—systemic scleroderma	4.62e-05	0.000615	CbGpPWpGaD
Loperamide—CALM1—Immune System—BLK—systemic scleroderma	4.57e-05	0.000608	CbGpPWpGaD
Loperamide—CALM2—Immune System—BLK—systemic scleroderma	4.57e-05	0.000608	CbGpPWpGaD
Loperamide—CALM1—Disease—CD247—systemic scleroderma	4.56e-05	0.000606	CbGpPWpGaD
Loperamide—CALM2—Disease—CD247—systemic scleroderma	4.56e-05	0.000606	CbGpPWpGaD
Loperamide—CALM3—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.54e-05	0.000603	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—HSPG2—systemic scleroderma	4.47e-05	0.000594	CbGpPWpGaD
Loperamide—CALM2—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.39e-05	0.000584	CbGpPWpGaD
Loperamide—CALM1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.39e-05	0.000584	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—TGFB1—systemic scleroderma	4.36e-05	0.000579	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—CCL2—systemic scleroderma	4.35e-05	0.000579	CbGpPWpGaD
Loperamide—CALM3—Metabolism—HSPG2—systemic scleroderma	4.35e-05	0.000578	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—EDN1—systemic scleroderma	4.29e-05	0.000571	CbGpPWpGaD
Loperamide—CALM2—Metabolism—HSPG2—systemic scleroderma	4.2e-05	0.000559	CbGpPWpGaD
Loperamide—CALM1—Metabolism—HSPG2—systemic scleroderma	4.2e-05	0.000559	CbGpPWpGaD
Loperamide—CALM3—Immune System—CTLA4—systemic scleroderma	3.87e-05	0.000515	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.86e-05	0.000514	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—RHOB—systemic scleroderma	3.85e-05	0.000513	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—HSPG2—systemic scleroderma	3.78e-05	0.000503	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EDN1—systemic scleroderma	3.76e-05	0.0005	CbGpPWpGaD
Loperamide—CALM2—Immune System—CTLA4—systemic scleroderma	3.74e-05	0.000498	CbGpPWpGaD
Loperamide—CALM1—Immune System—CTLA4—systemic scleroderma	3.74e-05	0.000498	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—RHOB—systemic scleroderma	3.73e-05	0.000496	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—RHOB—systemic scleroderma	3.73e-05	0.000496	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—CCL2—systemic scleroderma	3.68e-05	0.000489	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HSPG2—systemic scleroderma	3.63e-05	0.000483	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—NOS3—systemic scleroderma	3.54e-05	0.00047	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HSPG2—systemic scleroderma	3.52e-05	0.000468	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HSPG2—systemic scleroderma	3.52e-05	0.000468	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CSK—systemic scleroderma	3.51e-05	0.000467	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—NOS3—systemic scleroderma	3.42e-05	0.000455	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—NOS3—systemic scleroderma	3.42e-05	0.000455	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CSK—systemic scleroderma	3.4e-05	0.000452	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CSK—systemic scleroderma	3.4e-05	0.000452	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CTGF—systemic scleroderma	3.38e-05	0.00045	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—EDN1—systemic scleroderma	3.33e-05	0.000443	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—HSPG2—systemic scleroderma	3.29e-05	0.000438	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CTGF—systemic scleroderma	3.29e-05	0.000438	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—EDN1—systemic scleroderma	3.22e-05	0.000429	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—EDN1—systemic scleroderma	3.22e-05	0.000429	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CTGF—systemic scleroderma	3.19e-05	0.000424	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CTGF—systemic scleroderma	3.19e-05	0.000424	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-DQB1—systemic scleroderma	3.19e-05	0.000424	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EDN1—systemic scleroderma	3.18e-05	0.000423	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—HSPG2—systemic scleroderma	3.1e-05	0.000413	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-DQB1—systemic scleroderma	3.08e-05	0.00041	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-DQB1—systemic scleroderma	3.08e-05	0.00041	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1A—systemic scleroderma	3.03e-05	0.000403	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD40LG—systemic scleroderma	3.01e-05	0.0004	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CCL2—systemic scleroderma	2.93e-05	0.00039	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1A—systemic scleroderma	2.93e-05	0.000389	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1A—systemic scleroderma	2.93e-05	0.000389	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD40LG—systemic scleroderma	2.91e-05	0.000387	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD40LG—systemic scleroderma	2.91e-05	0.000387	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CTGF—systemic scleroderma	2.87e-05	0.000381	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—NOS3—systemic scleroderma	2.61e-05	0.000348	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CCL2—systemic scleroderma	2.57e-05	0.000342	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CTGF—systemic scleroderma	2.5e-05	0.000332	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CTGF—systemic scleroderma	2.35e-05	0.000313	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TGFB1—systemic scleroderma	2.34e-05	0.000311	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NOS3—systemic scleroderma	2.29e-05	0.000305	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CCL2—systemic scleroderma	2.28e-05	0.000303	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TGFB1—systemic scleroderma	2.26e-05	0.000301	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TGFB1—systemic scleroderma	2.26e-05	0.000301	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CCL2—systemic scleroderma	2.2e-05	0.000293	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CCL2—systemic scleroderma	2.2e-05	0.000293	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCL2—systemic scleroderma	2.17e-05	0.000289	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MMP9—systemic scleroderma	2.1e-05	0.000279	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.03e-05	0.00027	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EDN1—systemic scleroderma	1.97e-05	0.000262	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NOS3—systemic scleroderma	1.94e-05	0.000258	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EDN1—systemic scleroderma	1.9e-05	0.000253	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EDN1—systemic scleroderma	1.9e-05	0.000253	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MMP9—systemic scleroderma	1.84e-05	0.000245	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TGFB1—systemic scleroderma	1.73e-05	0.00023	CbGpPWpGaD
Loperamide—CALM3—Disease—NOS3—systemic scleroderma	1.71e-05	0.000228	CbGpPWpGaD
Loperamide—CALM2—Disease—NOS3—systemic scleroderma	1.66e-05	0.00022	CbGpPWpGaD
Loperamide—CALM1—Disease—NOS3—systemic scleroderma	1.66e-05	0.00022	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1B—systemic scleroderma	1.58e-05	0.00021	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MMP9—systemic scleroderma	1.55e-05	0.000207	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.54e-05	0.000205	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1B—systemic scleroderma	1.53e-05	0.000203	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1B—systemic scleroderma	1.53e-05	0.000203	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TGFB1—systemic scleroderma	1.52e-05	0.000202	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—NOS3—systemic scleroderma	1.47e-05	0.000196	CbGpPWpGaD
Loperamide—CALM3—Metabolism—NOS3—systemic scleroderma	1.43e-05	0.000191	CbGpPWpGaD
Loperamide—CALM2—Metabolism—NOS3—systemic scleroderma	1.39e-05	0.000185	CbGpPWpGaD
Loperamide—CALM1—Metabolism—NOS3—systemic scleroderma	1.39e-05	0.000185	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL2—systemic scleroderma	1.35e-05	0.000179	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL2—systemic scleroderma	1.3e-05	0.000173	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL2—systemic scleroderma	1.3e-05	0.000173	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFB1—systemic scleroderma	1.28e-05	0.00017	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—NOS3—systemic scleroderma	1.25e-05	0.000166	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NOS3—systemic scleroderma	1.2e-05	0.000159	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NOS3—systemic scleroderma	1.16e-05	0.000154	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NOS3—systemic scleroderma	1.16e-05	0.000154	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFB1—systemic scleroderma	1.13e-05	0.000151	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFB1—systemic scleroderma	1.1e-05	0.000146	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFB1—systemic scleroderma	1.1e-05	0.000146	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—NOS3—systemic scleroderma	1.09e-05	0.000145	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—NOS3—systemic scleroderma	1.02e-05	0.000136	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—systemic scleroderma	9.62e-06	0.000128	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—systemic scleroderma	9.31e-06	0.000124	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—systemic scleroderma	9.31e-06	0.000124	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFB1—systemic scleroderma	7.93e-06	0.000105	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFB1—systemic scleroderma	7.67e-06	0.000102	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFB1—systemic scleroderma	7.67e-06	0.000102	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NOS3—systemic scleroderma	6.7e-06	8.91e-05	CbGpPWpGaD
